+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Human Recombinant DNA: Global Markets

  • PDF Icon

    Report

  • 84 Pages
  • July 2022
  • Region: Global
  • BCC Research
  • ID: 5636770
Description Jump to:

Report Scope



This report highlights the current and future market potential for human recombinant DNA and provides a detailed analysis of the competitive environment, regulatory scenario, drivers, restraints, opportunities, trends and key players in the market. The report also provides market projections from 2022 through 2027. An in-depth discussion of strategic alliances, industry structures, competitive dynamics, and market forces are also provided.

Report Includes

  • 24 data tables and 8 additional tables
  • An overview of the global market for human recombinant DNA
  • Estimation of the market size and analyses of global market trends, with data from 2020, 2021 with projections of compound annual growth rates (CAGRs) through 2026
  • Highlights of the market potential for human recombinant DNA, based on product, application, and region
  • Coverage of history and future of human recombinant DNA, and latest technological advancements of the industry
  • Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast
  • Coverage of regulatory landscape, product recalls, pipeline products, and discussion on future perspective, strategies, and developments of the industry
  • Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies and a relevant patent analysis
  • Company profiles of major players within the industry AbbVie Inc., Amgen Inc., Eli Lilly, Sanofi

Table of Contents

Chapter 1 Introduction
  • Introduction
  • Study Goals and Objectives
  • Reasons for Doing the Study
  • Intended Audience
  • Scope and Format
  • Methodology
  • Market Estimates
  • Information Sources
  • Geographical Breakdown
  • Analyst's Credentials
  • Custom Research
  • Related Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Overview
  • Homologous Recombination (Hr)
  • Targets for Cancer Therapy
Chapter 4 Impact of Covid-19 Pandemic
Chapter 5 Market Dynamics
  • Market Drivers
  • Increasing Incidences of Chronic Diseases
  • Growing Aging Population
  • Advancements in Manufacturing Technologies
  • Market Restraints
  • Price Controls
  • Entry of Biosimilars
  • Opportunities
  • Untapped Potential in Emerging Markets
Chapter 6 Market Breakdown by Product Type
  • Human Protein Replacements
  • Market Size and Forecast
  • Therapeutic Agents for Human Diseases
  • Market Size and Forecast
  • Vaccines
  • Types of Vaccines
  • Market Size and Forecast
Chapter 7 Market Breakdown by End-user
  • Biotechnology and Pharmaceutical Industry
  • Market Size and Forecast
  • Research Laboratories and Academic Institutes
  • Market Size and Forecast
Chapter 8 Market Breakdown by Region
  • Global Market by Region
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
Chapter 9 Competitive Landscape
  • Overview
Chapter 10 Company Profiles
  • Abbvie Inc.
  • Alexion Pharmaceuticals
  • Amgen Inc.
  • Eli Lilly
  • Merck & Co. Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Co Ltd.
List of Tables
Summary Table: Global Market for Human Recombinant DNA, by Region, Through 2027
Table 1: Estimated World Population and Annual Growth, by Selected Age Group, Through 2030
Table 2: Cancer Statistics Across Major Asian Countries, by Cancer Site/Type, 2020
Table 3: Global Human Recombinant DNA Market, by Product Type, Through 2027
Table 4: Global Market for Human Protein Replacements, by Region, Through 2027
Table 5: Global Market for Therapeutic Agents for Human Diseases, by Region, Through 2027
Table 6: Vaccine Types
Table 7: Global Market for Vaccines, by Region, Through 2027
Table 8: Global Market for Human Recombinant DNA, by End User, Through 2027
Table 9: Global Market for Human Recombinant DNA in the Biotechnology and Pharmaceutical Industry, by Region, Through 2027
Table 10: Global Market for Human Recombinant DNA in Research Laboratories and Academic Institutes, by Region, Through 2027
Table 11: Global Market for Human Recombinant DNA, by Region, Through 2027
Table 12: North American Market for Human Recombinant DNA, by Product Type Through 2027
Table 13: North American Market for Human Recombinant DNA, by End User, Through 2027
Table 14: North American Market for Human Recombinant DNA, by Country, Through 2027
Table 15: European Market for Human Recombinant DNA, by Product Type, Through 2027
Table 16: European Human Recombinant DNA Market, by End User, Through 2027
Table 17: European Market for Human Recombinant DNA, by Country, Through 2027
Table 18: Asia-Pacific Market for Human Recombinant DNA, by Product Type, Through 2027
Table 19: Asia-Pacific Human Recombinant DNA Market, by End User, Through 2027
Table 20: Asia-Pacific Market for Human Recombinant DNA, by Country, Through 2027
Table 21: Japan: Total Number of New Cancer Cases in Both Genders, 2020
Table 22: RoW Market for Human Recombinant DNA, by Product Type, Through 2027
Table 23: RoW Market for Human Recombinant DNA, by End User, Through 2027
Table 24: Leading Market Players in the Human Recombinant DNA Market Ecosystem
Table 25: AbbVie Inc.: Business Segments
Table 26: AbbVie Inc.: Financial Performance, Through 2020
Table 27: Amgen: Financial Performance, Through 2020
Table 28: Eli Lilly: Business Segments
Table 29: Eli Lilly: Financial Performance, 2018-2020
Table 30: Sanofi: Business Segments
Table 31: Sanofi: Financial Performance, 2018-2020

List of Figures
Summary Figure A: Global Market for Human Recombinant DNA, by Region, 2020-2027
Summary Figure B: Global Market Shares of Human Recombinant DNA, by Region, 2021
Figure 1: Global Market Shares of Human Recombinant DNA, by Product Type, 2021
Figure 2: Global Market for Human Recombinant DNA, by Product Type, 2020-2027
Figure 3: Global Market for Human Protein Replacements, 2020-2027
Figure 4: Global Market for Therapeutic Agents for Human Diseases, 2020-2027
Figure 5: Evolution of Vaccine Technologies
Figure 6: Global Market for Vaccines, 2020-2027
Figure 7: Global Market Shares of Human Recombinant DNA, by End User, 2021
Figure 8: Global Market for Human Recombinant DNA, by End User, 2020-2027
Figure 9: Global Market for Human Recombinant DNA in the Biotechnology and Pharmaceutical Industry, 2020-2027
Figure 10: Global Market for Human Recombinant DNA in Research Laboratories and Academic Institutes, 2020-2027
Figure 11: Global Market Shares of Human Recombinant DNA, by Region, 2021
Figure 12: North American Market Shares of Human Recombinant DNA, by Product Type, 2021
Figure 13: North American Market Shares of Human Recombinant DNA, by End User, 2021
Figure 14: North American Market Shares of Human Recombinant DNA, by Country, 2021
Figure 15: U.S. Market for Human Recombinant DNA, 2020-2027
Figure 16: Canadian Market for Human Recombinant DNA, 2020-2027
Figure 17: European Market Shares of Human Recombinant DNA, by Product Type, 2021
Figure 18: European Human Recombinant DNA Market, Market Shares, by End User, 2021
Figure 19: European Market Shares of Human Recombinant DNA, by Country, 2021
Figure 20: Geriatric Population in Germany, 2000-2030
Figure 21: German Market for Human Recombinant DNA, 2020-2027
Figure 22: U.K. Market for Human Recombinant DNA, 2020-2027
Figure 23: French Market for Human Recombinant DNA, 2020-2027
Figure 24: Italian Market for Human Recombinant DNA, 2020-2027
Figure 25: Spanish Market for Human Recombinant DNA, 2020-2027
Figure 26: Rest of Europe Market for Human Recombinant DNA, 2020-2027
Figure 27: Asia-Pacific Market Shares of Human Recombinant DNA, by Product Type, 2021
Figure 28: Asia-Pacific Human Recombinant DNA Market, Market Shares, by End User, 2021
Figure 29: Asia-Pacific Market Shares of Human Recombinant DNA, by Country, 2021
Figure 30: New Cancer Cases in China, 2020
Figure 31: Distribution of New Cancer Cases in China, 2020
Figure 32: Chinese Market for Human Recombinant DNA, 2020-2027
Figure 33: Japanese Market for Human Recombinant DNA, 2020-2027
Figure 34: Indian Market for Human Recombinant DNA, 2020-2027
Figure 35: Rest of Asia-Pacific Market for Human Recombinant DNA, 2020-2027
Figure 36: New Cancer Cases in Africa, 2020
Figure 37: RoW Market Shares of Human Recombinant DNA, by Product Type, 2021
Figure 38: RoW Market Shares of Human Recombinant DNA, by End User, 2021
Figure 39: AbbVie Inc.: Net Revenue, by Business Segment, 2020
Figure 40: AbbVie Inc.: Net Revenue, by Region, 2020
Figure 41: Amgen: Total Sales, by Product, 2020
Figure 42: Amgen: Total Revenue, by Region, 2020
Figure 43: Eli Lilly: Total Sales, by Product Segment, 2020
Figure 44: Eli Lilly: Total Revenue, by Region, 2020
Figure 45: Sanofi: Net Sales, by Business Segment, 2020
Figure 46: Sanofi: Net Sales, by Region, 2020

Executive Summary

Recombinant DNA technology (RDT) is essential for improving health conditions, primarily by developing new vaccines and pharmaceuticals. The treatment strategies are improved by developing diagnostics kits, monitoring devices and new therapeutic approaches. Additionally, many other industries such as agriculture are benefiting from the research conducted on genetically modified organisms (GMO), for example microorganisms that are considered clean fuel producers and bio degraders.

Advances in oncology research for discovering underlying molecular mechanisms of cancerous cells to develop novel therapeutics is benefitting the market. The rising number of advanced cancer cases worldwide has significantly increased the need for developing DNA damage-response drugs. These drugs can improve cancer survival by providing a selective and well-tolerated treatment approach.

Regulatory approvals that delay product marketing can adversely impact manufacturer revenues. Similarly, a delay in post-approval of a drug product for another therapeutic indication increases clinical trial costs and potentially affects the labeling and approval status of currently marketed products.

Companies Mentioned

  • Abbvie Inc.
  • Alexion Pharmaceuticals
  • Amgen Inc.
  • Eli Lilly
  • Merck & Co. Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Co Ltd.

Table Information

Report AttributeDetails
No. of Pages84
PublishedJuly 2022
Forecast Period2022 - 2027
Estimated Market Value ( USD ) in 2022 $ 348.7 Billion
Forecasted Market Value ( USD ) by 2027 $ 496.9 Billion
Compound Annual Growth Rate7.3%
Regions CoveredGlobal
No. of Companies Mentioned7

Related Topics

Related Reports

Recombinant DNA Technology Market Size, Share and Trends Analysis Report by Product (Medical, Non-Medical), Component (Expression System), Application, End-use 2024-2030 - Product Image

Recombinant DNA Technology Market Size, Share and Trends Analysis Report by Product (Medical, Non-Medical), Component (Expression System), Application, End-use 2024-2030

  • Report
  • 100 Pages
  • Global
From
Recombinant DNA Technology Market Report by Product, Component, Application, End User, and Region 2024-2032 - Product Image

Recombinant DNA Technology Market Report by Product, Component, Application, End User, and Region 2024-2032

  • Report
  • 139 Pages
  • Global
From
Recombinant DNA Technology Global Market Report 2024 - Product Image

Recombinant DNA Technology Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Recombinant DNA Technology Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Recombinant DNA Technology Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 120 Pages
  • Global
From
Recombinant DNA Technology - Global Strategic Business Report - Product Image

Recombinant DNA Technology - Global Strategic Business Report

  • Report
  • 88 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.